Cancer drugs get a 30% margin cap: Why the govt made the move and how it helps patients

New Delhi: The Centre has capped trade margins on all non-scheduled anti-cancer drugs at 30% of MRP, a move expected to reduce medicine prices and save cancer patients around Rs 2,500 crore annually.

The Centre on Thursday decided to cap trade margins at 30 per cent of the maximum retail price (MRP) for all non-scheduled anti-cancer drugs. The measure covers branded and generic medicines, as well as domestically manufactured and imported drugs, including patented and non-patented products.

The government said the decision is aimed at addressing excessive trade mark-ups, improving the affordability of cancer medicines and ensuring continued availability of these treatments.

What does the 30% cap mean?

Under the new measure, the trade margin on non-scheduled anti-cancer medicines will be limited to 30 per cent of their MRP. The government has estimated that the intervention could lead to reductions of up to 70 per cent in the MRP of affected medicines.

The policy is intended to reduce the amount patients pay for medicines by limiting the margins added across the trade and distribution chain. The government expects this to lower out-of-pocket expenditure for people undergoing cancer treatment.

According to official estimates cited in reports, the trade-margin cap could result in annual savings of around Rs 2,500 crore for cancer patients. The savings are expected to come through lower prices for medicines covered by the measure.

The decision is particularly significant for patients who require prolonged or expensive cancer treatment, where medicine costs can form a substantial part of overall healthcare expenditure.

Policy builds on 2019 intervention

The latest decision follows a similar intervention introduced in 2019. According to official sources cited by ANI, that measure resulted in reported annual savings of Rs 984 crore across 526 brands.

The latest policy extends the approach to all non-scheduled anti-cancer drugs and covers medicines across different categories, including branded, generic, domestic, imported, patented and non-patented products.

Cancer treatment can involve significant and recurring medicine expenses. By restricting trade margins, the government is seeking to make a wider range of anti-cancer medicines more affordable while maintaining their availability.

The key impact for patients will depend on how the new margin cap is implemented across the distribution chain and reflected in the prices of individual medicines. The government has projected substantial savings, but the actual reduction will vary depending on the medicine and its existing pricing structure.

What changes for cancer patients?

The decision targets the trade component of medicine pricing rather than introducing a blanket price reduction for every cancer drug. Its stated objective is to address high trade mark-ups on non-scheduled medicines, which are not subject to the same price-control framework as scheduled drugs.

The broader policy significance lies in extending the trade-margin approach across all non-scheduled anti-cancer medicines, regardless of whether they are branded or generic, imported or domestic, or patented or non-patented. If the projected reductions materialise, patients could see lower medicine bills and reduced out-of-pocket spending.

However, the extent of the benefit will depend on implementation, compliance and the prices at which individual medicines are currently sold. The government estimates annual savings of about Rs 2,500 crore, building on the savings reported following the 2019 intervention.